Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma

Hepatology

Volumn 62, Issue 4, 2015, Pages 1111-1121

  Seyal, Adeel R ^a   Gonzalez Guindalini, Fernanda D ^a   Arslanoglu, Atilla ^a   Harmath, Carla B ^a   Lewandowski, Robert J ^a   Salem, Riad ^a   Yaghmai, Vahid ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER RADIOTHERAPY; CORRELATION COEFFICIENT; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REPRODUCIBILITY; STUDENT T TEST; TRANSARTERIAL RADIOEMBOLIZATION; TREATMENT RESPONSE; WILCOXON SIGNED RANKS TEST; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RADIOTHERAPY; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84942553752     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27915     Document Type: Article

References (42)

1. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed August 6, 2014.
2. Kudo M. The 2008 Okuda lecture. Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol 2010;25:439-452.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
4. Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009;115:616-623.
5. Keppke AL, Salem R, Reddy D, Huang J, Jin J, Larson AC, et al. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. AJR Am J Roentgenol 2007;188:768-775.
6. Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004;240:900-909.
7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
8. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
9. Horger M, Lauer UM, Schraml C, Berg CP, Koppenhofer U, Claussen CD, et al. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer 2009;9:208.
10. Atassi B, Bangash AK, Bahrani A, Pizzi G, Lewandowski RJ, Ryu RK, et al. Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics 2008;28:81-99.
11. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-4300.
12. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
13. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
14. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
15. Lencioni R. New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma. Clin Cancer Res 2013;19:1312-1314.
16. Verslype C, Rosmorduc O, Rougier P. Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl. 7):vii41-vii48.
17. Jung ES, Kim JH, Yoon EL, Lee HJ, Lee SJ, Suh SJ, et al. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol 2013;58:1181-1187.
18. Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011;55:1309-1316.
19. Li H, Guo Z, Si T, Wang H. EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation. Eur J Gastroenterol Hepatol 2013;25:620-627.
20. Prajapati HJ, Spivey JR, Hanish SI, El-Rayes BF, Kauh JS, Chen Z, et al. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol 2013;24:965-973.
21. Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 2012;262:708-718.
22. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
23. Foley WD, Mallisee TA, Hohenwalter MD, Wilson CR, Quiroz FA, Taylor AJ. Multiphase hepatic CT with a multirow detector CT scanner. AJR Am J Roentgenol 2000;175:679-685.
24. Laghi A, Iannaccone R, Rossi P, Carbone I, Ferrari R, Mangiapane F, et al. Hepatocellular carcinoma: detection with triple-phase multi-detector row helical CT in patients with chronic hepatitis. Radiology 2003;226:543-549.
25. Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 2010;303:1062-1069.
26. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
27. Memon K, Lewandowski RJ, Riaz A, Salem R. Yttrium 90 microspheres for the treatment of hepatocellular carcinoma. Recent Results Cancer Res 2013;190:207-224.
28. Salem R, Thurston KG. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006;17:1251-1278.
29. Radiological Society of North America Informatics. Radlex. http://www.radlex.org. Accessed August 6, 2014.
30. McBride GB. A proposal for strength-of-agreement criteria for Lin's concordance correlation coefficient. NIWA Client Report HAM2005-062. National Institute of Water & Atmospheric Research; 2005.
31. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
32. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140:497-507.
33. Lewandowski RJ, Mulcahy MF, Kulik LM, Riaz A, Ryu RK, Baker TB, et al. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010;255:955-965.
34. Sato Y, Watanabe H, Sone M, Onaya H, Sakamoto N, Osuga K, et al. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci 2013;118:16-22.
35. Erasmus JJ, Gladish GW, Broemeling L, Sabloff BS, Truong MT, Herbst RS, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003;21:2574-2582.
36. Suzuki C, Torkzad MR, Jacobsson H, Astrom G, Sundin A, Hatschek T, et al. Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. Acta Oncol 2010;49:509-514.
37. Lambert B, Sturm E, Mertens J, Oltenfreiter R, Smeets P, Troisi R, et al. Intra-arterial treatment with (9)(0)Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital. Eur J Nucl Med Mol Imaging 2011;38:2117-2124.
38. Vouche M, Kulik L, Atassi R, Memon K, Hickey R, Ganger D, et al. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: imaging analysis from a prospective randomized trial of Y90±sorafenib. Hepatology 2013;58:1655-1666.
39. Vouche M, Salem R, Lewandowski RJ, Miller FH. Can volumetric ADC measurement help predict response to Y90 radioembolization in HCC? Abdom Imaging 2014. doi: 10.1007/s00261-014-0295-6.
40. Ozkavukcu E, Haliloglu N, Erden A. Post-treatment MRI findings of hepatocellular carcinoma. Diagn Interv Radiol 2009;15:111-120.
41. Moschouris H, Malagari K, Gkoutzios P, Kalokairinou M, Stamatiou K, Chatzimichail K, et al. Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography. Med Ultrason 2012;14:87-94.
42. Moschouris H, Malagari K, Papadaki MG, Kornezos I, Stamatiou K, Anagnostopoulos A, et al. mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization. Diagn Interv Radiol 2014;20:136-142.